Perspective Therapeutics(CATX) - 2024 Q4 - Annual Results

Exhibit 99.1 Perspective Therapeutics Provides Recent Business Highlights and Reports Fiscal Q1 2024 Results • Continued progress enrolling in its VMT-α-NET and VMT01 clinical trials • Disclosed a new internally discovered molecule that targets fibroblast activation protein-α • Announced the in-licensing of a technology that enables the use of antibodies to direct radiolabeled ligands to tumor sites • Raised $177.2 million in gross proceeds through various financing transactions and raised an additional $49 ...